FITC BrdU Flow Kit

Cell cycle assay human - THP-1

Experiment
Cell cycle assay human - THP-1
Product
FITC BrdU Flow Kit from BD Biosciences
Manufacturer
BD Biosciences

Protocol tips

Upstream tips
- Cells were seeded and treated with or without recombinant human CCL2 (50 mg/ml) for 24 hours.

Publication protocol

THP-1 cells grown in 24-well plates with or without recombinant human CCL2 (50 mg/ml) for 24 hours were incubated with bromodeoxyuridine at various time-points as described by the manufacturers (FITC BrdU flow kit, BD Pharmingen, San Diego, CA). THP1 cells were harvested, fixed and labelled with anti-BrdU fluorescein isothiocyanate antibody and 7-AAD to analyze cell cycle status by FCM.

Full paper   Login or join for free to view the full paper.

Reviews

FITC BrdU Flow Kit from BD Biosciences has not yet been reviewed for this experiment

We'd love it if you would be the first to write a review!

Discussion

Start your discussion

Share your thoughts or question with experts in your field

Start a discussion

Papers

Check out relevant papers found by Labettor's AI that are relevant for performing Cell cycle assay human - THP-1 using FITC BrdU Flow Kit from BD Biosciences.

Paper title
The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells
Full paper
Login or join for free to view the full paper.

Manufacturer protocol

Download the product protocol from BD Biosciences for FITC BrdU Flow Kit below.

Download PDF Download manufacturer protocol

Videos

Check out videos that might be relevant for performing Cell cycle assay human - THP-1 using FITC BrdU Flow Kit from BD Biosciences. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.

We haven't found any additional videos for this experiment / product combination yet.

Outsource your experiment

Fill out your contact details and receive price quotes in your Inbox

  Outsource experiment
Become shareholder Discussions About us Contact Privacy Terms